Recent Developments and Challenges in Molecular-Targeted Therapy of Non-Small-Cell Lung Cancer.
Rohilla, S
Singh, M
Alzarea, SI
Almalki, WH
Al-Abbasi, FA
Kazmi, I
Afzal, O
Altamimi, ASA
Singh, SK
Chellappan, DK
Dua, K
Gupta, G
- Publisher:
- Begell House
- Publication Type:
- Journal Article
- Citation:
- J Environ Pathol Toxicol Oncol, 2023, 42, (1), pp. 27-50
- Issue Date:
- 2023
Closed Access
Filename | Description | Size | |||
---|---|---|---|---|---|
21974873_12718785780005671.pdf | Published version | 7.84 MB | Adobe PDF |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Rohilla, S | |
dc.contributor.author | Singh, M | |
dc.contributor.author | Alzarea, SI | |
dc.contributor.author | Almalki, WH | |
dc.contributor.author | Al-Abbasi, FA | |
dc.contributor.author | Kazmi, I | |
dc.contributor.author | Afzal, O | |
dc.contributor.author | Altamimi, ASA | |
dc.contributor.author | Singh, SK | |
dc.contributor.author | Chellappan, DK | |
dc.contributor.author |
Dua, K |
|
dc.contributor.author | Gupta, G | |
dc.date.accessioned | 2024-02-02T00:13:44Z | |
dc.date.available | 2024-02-02T00:13:44Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | J Environ Pathol Toxicol Oncol, 2023, 42, (1), pp. 27-50 | |
dc.identifier.issn | 0731-8898 | |
dc.identifier.issn | 2162-6537 | |
dc.identifier.uri | http://hdl.handle.net/10453/175259 | |
dc.description.abstract | Treatment of lung cancer with conventional therapies, which include radiation, surgery, and chemotherapy results in multiple undesirable adverse or side effects. The major clinical challenge in developing new drug therapies for lung cancer is resistance, which involves mutations and disturbance in various signaling pathways. Molecular abnormalities related to epidermal growth factor receptor (EGFR), v-Raf murine sarcoma viral oncogene homolog B1 (B-RAF) Kirsten rat sarcoma virus (KRAS) mutations, translocation of the anaplastic lymphoma kinase (ALK) gene, mesenchymal-epithelial transition factor (MET) amplification have been studied to overcome the resistance and to develop new therapies for non-small cell lung cancer (NSCLC). But, inevitable development of resistance presents limits the clinical benefits of various new drugs. Here, we review current progress in the development of molecularly targeted therapies, concerning six clinical biomarkers: EGFR, ALK, MET, ROS-1, KRAS, and B-RAF for NSCLC treatment. | |
dc.format | ||
dc.language | eng | |
dc.publisher | Begell House | |
dc.relation.ispartof | J Environ Pathol Toxicol Oncol | |
dc.relation.isbasedon | 10.1615/JEnvironPatholToxicolOncol.2022042983 | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject.classification | Oncology & Carcinogenesis | |
dc.subject.classification | 3211 Oncology and carcinogenesis | |
dc.subject.classification | 3214 Pharmacology and pharmaceutical sciences | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Mice | |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung | |
dc.subject.mesh | Lung Neoplasms | |
dc.subject.mesh | Molecular Targeted Therapy | |
dc.subject.mesh | Proto-Oncogene Proteins p21(ras) | |
dc.subject.mesh | ErbB Receptors | |
dc.subject.mesh | Mutation | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Mice | |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung | |
dc.subject.mesh | Lung Neoplasms | |
dc.subject.mesh | Mutation | |
dc.subject.mesh | Proto-Oncogene Proteins p21(ras) | |
dc.subject.mesh | Molecular Targeted Therapy | |
dc.subject.mesh | ErbB Receptors | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Mice | |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung | |
dc.subject.mesh | Lung Neoplasms | |
dc.subject.mesh | Molecular Targeted Therapy | |
dc.subject.mesh | Proto-Oncogene Proteins p21(ras) | |
dc.subject.mesh | ErbB Receptors | |
dc.subject.mesh | Mutation | |
dc.title | Recent Developments and Challenges in Molecular-Targeted Therapy of Non-Small-Cell Lung Cancer. | |
dc.type | Journal Article | |
utslib.citation.volume | 42 | |
utslib.location.activity | United States | |
pubs.organisational-group | University of Technology Sydney | |
pubs.organisational-group | University of Technology Sydney/Faculty of Health | |
pubs.organisational-group | University of Technology Sydney/Faculty of Health/Public Health | |
utslib.copyright.status | closed_access | * |
dc.date.updated | 2024-02-02T00:13:42Z | |
pubs.issue | 1 | |
pubs.publication-status | Published | |
pubs.volume | 42 | |
utslib.citation.issue | 1 |
Abstract:
Treatment of lung cancer with conventional therapies, which include radiation, surgery, and chemotherapy results in multiple undesirable adverse or side effects. The major clinical challenge in developing new drug therapies for lung cancer is resistance, which involves mutations and disturbance in various signaling pathways. Molecular abnormalities related to epidermal growth factor receptor (EGFR), v-Raf murine sarcoma viral oncogene homolog B1 (B-RAF) Kirsten rat sarcoma virus (KRAS) mutations, translocation of the anaplastic lymphoma kinase (ALK) gene, mesenchymal-epithelial transition factor (MET) amplification have been studied to overcome the resistance and to develop new therapies for non-small cell lung cancer (NSCLC). But, inevitable development of resistance presents limits the clinical benefits of various new drugs. Here, we review current progress in the development of molecularly targeted therapies, concerning six clinical biomarkers: EGFR, ALK, MET, ROS-1, KRAS, and B-RAF for NSCLC treatment.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph